Retatrutide Research
Reta Peptides Explained
The term 'reta peptides' is used informally to refer to retatrutide, a single investigational peptide compound rather than a family. Retatrutide belongs to the incretin-mimetic class, alongside semaglutide and tirzepatide, but is unique as the first triple-receptor agonist in Phase 3 trials.
Key facts
- Molecule
- Retatrutide (LY3437943)
- Peptide class
- Triple incretin agonist
- Related peptides
- Semaglutide, tirzepatide, liraglutide (same drug class)
Is there a 'reta peptide family'?
Not in a formal sense. Retatrutide is a single molecule. The broader class it belongs to is the incretin-mimetic peptide family, which includes GLP-1 agonists (semaglutide, liraglutide), dual GIP/GLP-1 agonists (tirzepatide), and now the triple agonist retatrutide.
Why is retatrutide grouped with other incretins?
All incretin-class peptides share overlapping receptor targets and are derived from or modelled on native gut hormones (GLP-1, GIP, glucagon). Retatrutide extends the class by activating all three receptors within one peptide chain.
Research material referenced
Retatrutide 10mg — third-party HPLC tested
Extended research context
The Retatrutide Research deep dive
Deep dive: how the triple-agonist scaffold was engineered
Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance — the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.
The TRIUMPH Phase 3 programme in context
TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator — FDA, EMA, or MHRA — has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.
How retatrutide differs from tirzepatide and semaglutide at the mechanism level
Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press — but the pharmacology is more nuanced than the label implies.
Research applications
- ▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
- ▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
- ▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
- ▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
- ▸Reference material for teaching incretin pharmacology in university-level courses
Handling checklist
- ✓Store lyophilised vials at −20 °C; protect from light and humidity
- ✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
- ✓Once reconstituted, store at 2–8 °C and use within 28 days
- ✓Verify batch CoA — HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
- ✓Do not administer to humans or animals — research use only
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Confusing retatrutide with tirzepatide in supplier catalogues
Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.
✗ Using tap or filtered water for reconstitution
Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water — never lab DI water.
✗ Storing reconstituted solution at room temperature
Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- Is retatrutide the same molecule as LY3437943?
- What is the correct spelling: retatrutide or retatrutid?
- Is retatrutide a GLP-1 drug?
- Which company makes retatrutide?
- When will retatrutide be FDA approved?
- Is retatrutide legal in the UK?
Frequently asked questions
- Are there multiple 'reta' peptides for sale?
- No — retatrutide is a single compound. Any 'reta' product refers to the same molecule under different presentations.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- RefCoskun et al., Cell Metabolism 2022cell.com
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05869903) — Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05882045) — Retatrutide in obesity + T2DMclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05936151) — Retatrutide + established CVDclinicaltrials.gov
- PubMedJastreboff et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity — NEJM 2023 (PMID 37356472)pubmed.ncbi.nlm.nih.gov
- PubMedRosenstock et al., Retatrutide in adults with T2D — Lancet 2023 (PMID 37356473)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Retatrutide (CID 156588324)pubchem.ncbi.nlm.nih.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
- GuidelineGoogle — Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
Jack Muncaster · Founder, UK Peptides
Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.
More Retatrutide Research articles
- Retatrutide vs Semaglutide vs Tirzepatide: Receptor ComparisonCompare retatrutide, semaglutide and tirzepatide by receptor targets, molecular structure, developer and regulatory status. Peer-reviewed research overview.
- Is Retatrutide FDA Approved? Regulatory Status ExplainedRetatrutide is not FDA approved. It is an investigational peptide in the Phase 3 TRIUMPH programme. Current EMA, MHRA and FDA regulatory status explained.
- Retatrutide Molecular Structure and PropertiesRetatrutide molecular structure: 39-residue peptide, ~4,731 Da molecular weight, fatty-acid conjugation at Lys17, and physicochemical properties.
- What Is a Triple Agonist? Retatrutide's GIP/GLP-1/Glucagon MechanismA triple agonist is a single molecule that activates three receptors. Retatrutide activates GIP, GLP-1 and glucagon receptors — mechanism explained.
- Retatrutide Spelling: Retratrutide and Common VariantsRetatrutide is the correct spelling — not retratrutide, retatrutida, or retatrudide. Common misspellings, INN naming, and the correct pronunciation.
Popular across the research hub
One flagship guide from every other research category — keep exploring.
- GHK-Cu (Copper Peptide)GHK-Cu CAS Number and Chemical Identity
- TB-500 (Thymosin β4 fragment)Is TB-500 the Same as Full-Length Thymosin Beta-4?
- BPC-157 (Pentadecapeptide)BPC-157 Pentadecapeptide Explained
- CJC-1295 & IpamorelinCJC-1295 Half-Life: DAC vs Non-DAC
- Peptide ReferenceWhat Is the Polypeptide Group?
- Bacteriostatic WaterBacteriostatic Water vs Sterile Water